Biogen Acquires Nightstar Therapeutics in $800 Million Gene Therapy Deal

Health care giant Biogen has announced plans to acquire gene therapy company Nightstar Therapeutics. In a statement on Monday, Biogen said that it will acquire Nightstar for $25.50 per share pending customary closing conditions. The deal, which values Nightstar at $800 million after expenses, is an all-cash acquisition that will give Biogen a foothold in […]

Roche Bids $4.3 Billion for U.S.-Based Gene Therapy Specialist Spark

Roche Holding AG’s $4.8 billion bid for Spark Therapeutics Inc. raises the stakes further in the bidding for makers of therapies that promise to treat rare, debilitating diseases by correcting inborn flaws in DNA. Purchasing Philadelphia-based Spark will put Roche near the front of the pack with Basel-based neighbor Novartis AG in developing the promising […]